I-Derm Pharma is developing a first-in-class oral therapy for moderate-to-severe psoriasis. Our proprietary small-molecule family targets an inflammatory pathway and has shown strong preclinical efficacy in chimeric mice with psoriatic human skin grafts, alongside a favorable safety profile. We are advancing our lead candidate toward IND with robust IP and are preparing for next milestones and strategic collaborations.